CN107583036B - 一种重组人干扰素α1b***膨胀栓及其制备方法 - Google Patents
一种重组人干扰素α1b***膨胀栓及其制备方法 Download PDFInfo
- Publication number
- CN107583036B CN107583036B CN201711059492.1A CN201711059492A CN107583036B CN 107583036 B CN107583036 B CN 107583036B CN 201711059492 A CN201711059492 A CN 201711059492A CN 107583036 B CN107583036 B CN 107583036B
- Authority
- CN
- China
- Prior art keywords
- parts
- suppository
- extract
- vaginal
- recombinant human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000829 suppository Substances 0.000 title claims abstract description 89
- 108010002492 human interferon alfa-1b Proteins 0.000 title claims description 56
- 102000000707 human interferon alfa-1b Human genes 0.000 title claims description 56
- 238000002360 preparation method Methods 0.000 title abstract description 21
- 239000011159 matrix material Substances 0.000 claims abstract description 38
- 229920000642 polymer Polymers 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims description 41
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 33
- 239000000194 fatty acid Substances 0.000 claims description 33
- 229930195729 fatty acid Natural products 0.000 claims description 33
- -1 fatty acid esters Chemical class 0.000 claims description 33
- 239000003814 drug Substances 0.000 claims description 29
- 239000006216 vaginal suppository Substances 0.000 claims description 25
- 210000002826 placenta Anatomy 0.000 claims description 22
- 241001071917 Lithospermum Species 0.000 claims description 20
- 239000010975 amethyst Substances 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 20
- 240000006688 Telosma cordata Species 0.000 claims description 19
- 235000017352 Telosma cordata Nutrition 0.000 claims description 19
- 229940120293 vaginal suppository Drugs 0.000 claims description 19
- 238000001816 cooling Methods 0.000 claims description 16
- 238000005507 spraying Methods 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 13
- 238000002844 melting Methods 0.000 claims description 11
- 230000008018 melting Effects 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 239000000155 melt Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 9
- 150000002632 lipids Chemical class 0.000 claims description 9
- 229920001610 polycaprolactone Polymers 0.000 claims description 9
- 239000004632 polycaprolactone Substances 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 8
- 238000007493 shaping process Methods 0.000 claims description 8
- 238000009210 therapy by ultrasound Methods 0.000 claims description 8
- 210000004177 elastic tissue Anatomy 0.000 claims description 7
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 7
- 239000004626 polylactic acid Substances 0.000 claims description 7
- 229920002635 polyurethane Polymers 0.000 claims description 7
- 239000004814 polyurethane Substances 0.000 claims description 7
- 239000004745 nonwoven fabric Substances 0.000 claims description 5
- 229920006158 high molecular weight polymer Polymers 0.000 claims 2
- 239000007921 spray Substances 0.000 claims 1
- 102100036532 Interferon alpha-8 Human genes 0.000 abstract description 5
- 108010047126 interferon-alpha 8 Proteins 0.000 abstract description 5
- 230000000694 effects Effects 0.000 description 32
- 230000000052 comparative effect Effects 0.000 description 27
- 229920001577 copolymer Polymers 0.000 description 14
- 230000035945 sensitivity Effects 0.000 description 13
- 230000010339 dilation Effects 0.000 description 12
- 229920000742 Cotton Polymers 0.000 description 11
- 229940079593 drug Drugs 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 7
- 102000014150 Interferons Human genes 0.000 description 6
- 108010050904 Interferons Proteins 0.000 description 6
- 229940079322 interferon Drugs 0.000 description 6
- 241000193830 Bacillus <bacterium> Species 0.000 description 5
- 102100040018 Interferon alpha-2 Human genes 0.000 description 5
- 230000000857 drug effect Effects 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010046914 Vaginal infection Diseases 0.000 description 4
- 201000008100 Vaginitis Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000003385 bacteriostatic effect Effects 0.000 description 4
- 239000000084 colloidal system Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000005096 rolling process Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 108010078049 Interferon alpha-2 Proteins 0.000 description 3
- 244000137773 Viola philippica Species 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000207202 Gardnerella Species 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 108010079944 Interferon-alpha2b Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010071211 Vulvovaginal swelling Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- AWFYPPSBLUWMFQ-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=C2 AWFYPPSBLUWMFQ-UHFFFAOYSA-N 0.000 description 1
- 241000437896 Corydalis bungeana Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
- ISQRJFLLIDGZEP-CMWLGVBASA-N Sophoricoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C=2C(C3=C(O)C=C(O)C=C3OC=2)=O)C=C1 ISQRJFLLIDGZEP-CMWLGVBASA-N 0.000 description 1
- ISQRJFLLIDGZEP-KJRRRBQDSA-N Sophoricoside Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1ccc(C=2C(=O)c3c(O)cc(O)cc3OC=2)cc1 ISQRJFLLIDGZEP-KJRRRBQDSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000010227 cup method (microbiological evaluation) Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
编号 | 轴向膨胀值 | 径向膨胀值 | 重量差异 |
实施例1 | 1.92 | 1.91 | ±0.02% |
实施例2 | 1.88 | 1.87 | ±0.13% |
实施例3 | 1.87 | 1.88 | ±0.12% |
实施例4 | 1.82 | 1.84 | ±0.27% |
实施例5 | 1.82 | 1.82 | ±0.25% |
实施例6 | 1.79 | 1.80 | ±0.28% |
编号 | 4℃ | 25℃ | 37℃ |
实施例1 | 5.1×10<sup>8</sup> | 3.6×10<sup>8</sup> | 1.7×10<sup>8</sup> |
实施例2 | 4.9×10<sup>8</sup> | 3.1×10<sup>8</sup> | 8.4×10<sup>7</sup> |
实施例3 | 4.9×10<sup>8</sup> | 2.9×10<sup>8</sup> | 8.5×10<sup>7</sup> |
实施例4 | 4.7×10<sup>8</sup> | 2.2×10<sup>8</sup> | 7.8×10<sup>7</sup> |
实施例5 | 4.8×10<sup>8</sup> | 2.0×10<sup>8</sup> | 7.8×10<sup>7</sup> |
实施例6 | 4.4×10<sup>8</sup> | 1.8×10<sup>8</sup> | 7.1×10<sup>7</sup> |
对比例1 | 3.7×10<sup>7</sup> | 2.9×10<sup>4</sup> | 5.5×10<sup>2</sup> |
对比例2 | 4.0×10<sup>7</sup> | 3.5×10<sup>4</sup> | 5.0×10<sup>2</sup> |
对比例3 | 2.5×10<sup>8</sup> | 6.3×10<sup>7</sup> | 1.0×10<sup>7</sup> |
对比例4 | 2.8×10<sup>8</sup> | 7.2×10<sup>7</sup> | 2.1×10<sup>7</sup> |
对比例5 | 3.8×10<sup>8</sup> | 1.0×10<sup>8</sup> | 9.2×10<sup>7</sup> |
对比例6 | 3.6×10<sup>8</sup> | 1.2×10<sup>8</sup> | 9.5×10<sup>7</sup> |
编号 | 释放时间(h) |
实施例1 | 24 |
实施例2 | 20 |
实施例3 | 20 |
实施例4 | 18 |
实施例5 | 18 |
实施例6 | 20 |
对比例1 | 4 |
对比例2 | 10 |
抑菌圈直径(mm) | 敏感度 |
大于20 | 极敏 |
15-20 | 高敏 |
10-14 | 中敏 |
1-10 | 低敏 |
0 | 不敏 |
编号 | 菌液浓度(cfu/g) | 抑菌圈直径(mm) | 敏感度 |
实施例1 | 10<sup>5</sup>-10<sup>6</sup> | 27.20 | 极敏 |
实施例2 | 10<sup>5</sup>-10<sup>6</sup> | 26.72 | 极敏 |
实施例3 | 10<sup>5</sup>-10<sup>6</sup> | 25.26 | 极敏 |
实施例4 | 10<sup>5</sup>-10<sup>6</sup> | 25.17 | 极敏 |
实施例5 | 10<sup>5</sup>-10<sup>6</sup> | 24.88 | 极敏 |
实施例6 | 10<sup>5</sup>-10<sup>6</sup> | 24.26 | 极敏 |
对比例3 | 10<sup>5</sup>-10<sup>6</sup> | 14.13 | 中敏 |
对比例4 | 10<sup>5</sup>-10<sup>6</sup> | 11.36 | 中敏 |
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711059492.1A CN107583036B (zh) | 2017-11-01 | 2017-11-01 | 一种重组人干扰素α1b***膨胀栓及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711059492.1A CN107583036B (zh) | 2017-11-01 | 2017-11-01 | 一种重组人干扰素α1b***膨胀栓及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107583036A CN107583036A (zh) | 2018-01-16 |
CN107583036B true CN107583036B (zh) | 2020-04-24 |
Family
ID=61044208
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711059492.1A Active CN107583036B (zh) | 2017-11-01 | 2017-11-01 | 一种重组人干扰素α1b***膨胀栓及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107583036B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108403618A (zh) * | 2018-04-26 | 2018-08-17 | 霍尔果斯汉智医药科技有限公司 | 一种咪喹莫特***膨胀栓及其制备方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1291502A (zh) * | 1999-10-11 | 2001-04-18 | 常毅坚 | 一种治疗妇科疾病的中药丸剂 |
CN101313904A (zh) * | 2007-06-01 | 2008-12-03 | 北京德众万全药物技术开发有限公司 | 一种用于治疗外***炎的芬替康唑栓剂 |
CN103520264A (zh) * | 2013-10-11 | 2014-01-22 | 哈尔滨欧替药业有限公司 | 妇康***膨胀栓及其制备方法和检测方法 |
CN103751098A (zh) * | 2013-12-31 | 2014-04-30 | 哈尔滨欧替药业有限公司 | 重组人干扰素α2а***膨胀栓及其制备方法和检测方法 |
CN104352667A (zh) * | 2014-11-17 | 2015-02-18 | 刘岚 | 一种治疗非特异性***炎的药物及制备方法 |
CN105012938A (zh) * | 2015-06-30 | 2015-11-04 | 哈尔滨欧替药业有限公司 | 重组人干扰素α2b***膨胀栓及其制备方法和检测方法 |
CN106692788A (zh) * | 2017-03-01 | 2017-05-24 | 秦玉成 | 一种用于治疗妇科病的外用药剂 |
-
2017
- 2017-11-01 CN CN201711059492.1A patent/CN107583036B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1291502A (zh) * | 1999-10-11 | 2001-04-18 | 常毅坚 | 一种治疗妇科疾病的中药丸剂 |
CN101313904A (zh) * | 2007-06-01 | 2008-12-03 | 北京德众万全药物技术开发有限公司 | 一种用于治疗外***炎的芬替康唑栓剂 |
CN103520264A (zh) * | 2013-10-11 | 2014-01-22 | 哈尔滨欧替药业有限公司 | 妇康***膨胀栓及其制备方法和检测方法 |
CN103751098A (zh) * | 2013-12-31 | 2014-04-30 | 哈尔滨欧替药业有限公司 | 重组人干扰素α2а***膨胀栓及其制备方法和检测方法 |
CN104352667A (zh) * | 2014-11-17 | 2015-02-18 | 刘岚 | 一种治疗非特异性***炎的药物及制备方法 |
CN105012938A (zh) * | 2015-06-30 | 2015-11-04 | 哈尔滨欧替药业有限公司 | 重组人干扰素α2b***膨胀栓及其制备方法和检测方法 |
CN106692788A (zh) * | 2017-03-01 | 2017-05-24 | 秦玉成 | 一种用于治疗妇科病的外用药剂 |
Also Published As
Publication number | Publication date |
---|---|
CN107583036A (zh) | 2018-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6503525B1 (en) | Absorbent article which maintains or improves skin health | |
CN102058900B (zh) | 一种具有防水性的创面防护用液体绷带及其制备方法 | |
ZA200101104B (en) | Absorbent article which maintains or improves skin health. | |
CN107596350B (zh) | 一种重组人干扰素ε***膨胀栓及其制备方法 | |
SE9703669D0 (sv) | Alster och beredning innefattande mjölksyrabakterier | |
EP1107719A1 (en) | Absorbent article which maintains or improves skin health | |
CN103301295A (zh) | 康妇消炎***膨胀栓及其制备方法和检测方法 | |
CN107583036B (zh) | 一种重组人干扰素α1b***膨胀栓及其制备方法 | |
AU709379B2 (en) | Transdermal formulation | |
CN104983585A (zh) | 一种疤痕用防晒硅凝胶及制备方法 | |
Martini et al. | Efficacy and Tolerability of Fitostimoline in Two Different Forms (Soaked Gauzes and Cream) and Citrizan Gel in the Topical Treatment of Second‐Degree Superficial Cutaneous Burns | |
EA029649B1 (ru) | Гель на основе полифенолов гранатовой кожуры для лечения воспалительных заболеваний в гинекологии и способ его приготовления | |
CN110680855B (zh) | 一种含有益生菌和中药组合物的***膨胀栓及其制备方法 | |
CN103520090B (zh) | 替硝唑***膨胀栓及其制备方法和检测方法 | |
CN107583035B (zh) | 一种重组人干扰素γ***膨胀栓及其制备方法 | |
CN103751098B (zh) | 重组人干扰素α2а***膨胀栓及其制备方法和检测方法 | |
CN109847019B (zh) | 一种用于卫生用品的抑菌组合物及其制备方法 | |
CN105012938B (zh) | 重组人干扰素α2b***膨胀栓及其制备方法和检测方法 | |
CN103536612A (zh) | 硝呋太尔-制霉素***膨胀栓及其制备方法和检测方法 | |
CN103494767B (zh) | 雌三醇***膨胀栓及其制备方法和检测方法 | |
CN103751267A (zh) | 苦参***膨胀栓及其制备方法和检测方法 | |
CN103520086A (zh) | 硝酸咪康唑***膨胀栓及其制备方法和检测方法 | |
CN103751097B (zh) | 氧氟沙星***膨胀栓及其制备方法和检测方法 | |
CN103735491B (zh) | 克林霉素磷酸酯***膨胀栓及其制备方法和检测方法 | |
CN103768005A (zh) | 酮康唑***膨胀栓及其制备方法和检测方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20211116 Address after: 150040 office building 7, Bohai Third Road, haping road concentration area, Harbin Economic Development Zone, Harbin, Heilongjiang Province Patentee after: Harbin Tianmei Pharmaceutical Co.,Ltd. Address before: 150069 No. 7, Bohai Third Road, Pingfang Industrial Zone, economic and Technological Development Zone, Harbin, Heilongjiang Province Patentee before: HARBIN OT PHARMACEUTICALS Co.,Ltd. Patentee before: Qiu Mingshi |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A recombinant human interferon a 1b vaginal expansion suppository and its preparation method Effective date of registration: 20230704 Granted publication date: 20200424 Pledgee: Harbin Kechuang Financing Guarantee Co.,Ltd. Pledgor: Harbin Tianmei Pharmaceutical Co.,Ltd. Registration number: Y2023230000060 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20200424 Pledgee: Harbin Kechuang Financing Guarantee Co.,Ltd. Pledgor: Harbin Tianmei Pharmaceutical Co.,Ltd. Registration number: Y2023230000060 |